BUSINESS

• Apeiron Begins PI Study of Neuroblastoma Immunotherapy Agent in Japan
  July 10, 2014

• Vital-Net Makes Miyagi-Based Dispensing Pharmacy Chain Ohno its Subsidiary
  July 10, 2014

• Bayer Yakuhin Sees Cancer Drugs as New Pillar
  July 9, 2014

• MTPC to Up Japan Sales Force by 200-300 Partly via Job Transfers
  July 9, 2014

• 31 Executives Received Annual Compensations for FY2013 of Over 100 Million Yen: Jiho Survey
  July 9, 2014

• MTPC Aspires to Derive 30% of Sales from Offshore Biz
  July 8, 2014

• Sanofi to Bounce Back with New Portfolios, Shift to “Mabs”: Pres.
  July 7, 2014

• Sanofi’s Prostate Cancer Drug Cabazitaxel Gets Japan OK
  July 7, 2014

• MTPC’s SGLT-2 Inhibitor Canaglu Wins Japan Approval
  July 7, 2014

• European Commission Approves Expanded Indication for Halaven for Earlier Use in Breast Cancer Treatment: Eisai
  July 7, 2014

• Nippon Kayaku Obtains Approval for Remicade Biosimilar
  July 7, 2014

• Sawai Preparing to File More Products for US Approval: Exec
  July 4, 2014

• Santen to Complete Acquisition of Ophthalmology Assets from Merck
  July 4, 2014

• Taiho Submits Application for Additional Indication of Febrile Neutropenia for Zosyn
  July 4, 2014

• BMKK Asks Major Law Firm to Conduct Independent Investigation of Clinical Research on Sprycel
  July 4, 2014

• Kyowa Kirin to Resume Development of Bardoxolone Methyl for CKD Patients with Type 2 Diabetes
  July 4, 2014

• Poteligeo Re-Filed for Approval of Additional Indication of Untreated CCR4-Positive ATL
  July 3, 2014

• Meiji Seika Pharma Wants to Make Cancer Drugs, Biologics 4th Biz Pillar
  July 3, 2014

• Genzyme Japan Submits NDA for Oral Gaucher’s Disease Drug
  July 3, 2014

• CMIC, JSR Set Up Joint Venture for Next-Generation Antibodies
  July 3, 2014

ページ

• « 先頭
• ‹ Prev
• …
• 559
• 560
• 561
• 562
• 563
• 564
• 565
• 566
• 567
• …
• Next ›
• 最終 »